Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells.

ABSTRACT: Only 40% of patients with advanced ovarian cancer survive more than 5 years. We have previously shown that pitavastatin induces regression of ovarian cancer xenografts in mice. To evaluate whether the response of ovarian cancer cells to pitavastatin is potentiated by farnesyl diphosphate synthase inhibitors or geranylgeraniol transferase I inhibitors, we evaluated combinations of pitavastatin with zoledronic acid, risedronate and GGTI-2133 in a panel of ovarian cancer cells. Pitavastatin (IC₅₀ = 0.6-14 μM), zoledronic acid (IC₅₀ = 21-57 μM), risedronate (IC₅₀ > 100 μM) or GGTI-2133 (IC₅₀ > 25 μM) inhibited the growth of ovarian cancer cell cultures. Combinations of pitavastatin with zoledronic acid displayed additive or synergistic effects in cel

SUBMITTER: Abdullah MI 

PROVIDER: S-EPMC5556066 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature